Not provided
Not provided
Not provided
Not provided
Not provided
The Sponsor decided to close enrollment to the study on Feb 14, 2023, in order to reallocate resources to other ongoing trilaciclib clinical trials.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This was a Phase 2, multicenter, open-label, single-arm study evaluating the safety and efficacy of trilaciclib administered prior to sacituzumab govitecan-hziy in participants with unresectable, locally advanced or metastatic triple-negative breast cancer (TNBC) who received at least 2 prior treatments, at least 1 in the metastatic setting.
The study included 3 study phases: Screening Phase, Treatment Phase, and Survival Follow-up Phase. The Treatment Phase began on the day of the first dose of study treatment and was completed at the Safety Follow-up Visit. Trilaciclib and sacituzumab govitecan-hziy were administered intravenously (IV) in 21-day cycles. Study drug administration continued until progressive disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or clinical progression as determined by the Investigator, unacceptable toxicity, withdrawal of consent, Investigator decision, or the end of the study, whichever occurred first. The first Survival Follow-up assessment occurred approximately 3 months after the Safety Follow-Up Visit and continued every 3 months until the end of the study (or death).
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Trilaciclib + Sacituzumab Govitecan-hziy | Experimental | Participants received trilaciclib + sacituzumab govitecan-hziy on days 1 & 8 of a 21 day cycle. Trilaciclib is administered first, followed by sacituzumab govitecan-hziy. Administer diluted trilaciclib solution as a 30-minute IV infusion to be completed within 4 hours prior to the start of sacituzumab govitecan-hziy. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Trilaciclib | Drug | Single-use, sterile powder to be reconstituted and further diluted with 250 milliliters (mL) of normal saline (sodium chloride solution 0.9%) or dextrose 5% in water (D5W) |
| Measure | Description | Time Frame |
|---|---|---|
| Progression Free Survival (PFS) | Progression free survival was defined as the time (months) from the date of the first dose of the study drug to the date of documented radiographic disease progression per RECIST v1.1 or death due to any cause, whichever comes first. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions | Up to approximately 23 months |
| Measure | Description | Time Frame |
|---|---|---|
| Objective Response Rate (ORR) | ORR was defined as the percentage of participants with the best overall response of confirmed complete response or confirmed partial response per RECIST v1.1 Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. | Up to approximately 24 months |
Not provided
Inclusion Criteria:
Adult ( ≥18 years of age), female or male participant with measurable (per RECIST v1.1), unresectable locally advanced or metastatic TNBC
Documentation of histologically or cytologically confirmed ER-negative, PR-negative, and HER2-negative tumor per the American Society of Clinical Oncology (ASCO) and the College of American Pathologists (ASCO/CAP) criteria.
Measurable disease as defined by RECIST v1.1.
Considered to be eligible to receive sacituzumab govitecan-hziy treatment, in the Investigator's judgment.
Participants must have received 2 or more prior lines of systemic therapy, at least one of them in the metastatic setting.
Radiation therapy for metastatic disease is permitted as long as the participant has at least 1 measurable lesion that has not been irradiated. Participants should be sufficiently recovered from the effects of radiation as determined by the Investigator but must have completed radiotherapy at least 2 weeks prior to enrollment.
ECOG performance status of 0 or 1.
Adequate organ function as demonstrated by the following laboratory values:
Resolution of nonhematologic toxicities from prior systemic therapy, radiation therapy, or surgical procedures to Common Terminology Criteria for Adverse Events (CTCAE) ≤ Grade 1 (except alopecia or peripheral neuropathy that may be Grade 2 or less).
Predicted life expectancy of ≥3 months.
Contraceptive use by men or women should be consistent with local guidelines regarding the methods of contraception for those participating in clinical studies.
Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form and in this protocol.
Exclusion Criteria:
Prior treatment with trilaciclib, sacituzumab govitecan-hziy, irinotecan, Trop-2 antibody drug conjugate, or any therapy with a topoisomerase-1 payload.
Participants with known brain metastasis at enrollment.
Participants with known Gilbert's disease or known homozygous for the UGT1A1*28 allele.
Participants with bone-only disease.
Malignancies other than TNBC within 3 years prior to enrollment. Participants with malignancies of a negligible risk of metastasis or death (e.g., risk of metastasis or death <5% at 5 years as determined by the Investigator) are eligible provided they meet all of the following criteria:
History of clinically significant gastrointestinal bleeding, intestinal obstruction, or gastrointestinal perforation within 6 months of enrollment.
Receipt of any investigational medication within 4 weeks, or at least 5 half-lives, whichever is greater, prior to the first dose of study treatment.
Receipt of any cytotoxic chemotherapy within 2 weeks or antibody treatment for cancer within 3 weeks prior to the first dose of study treatment.
Receipt of any high dose systemic corticosteroids within 2 weeks prior to the first dose of study treatment.
Current use of immunosuppressive medication, except for the following:
Use of oral or IV antibiotics within 2 weeks prior to enrollment.
QT corrected interval using Fridericia's formula (QTcF) >480 msec at screening (confirmed on repeat). For participants with ventricular pacemakers, QTcF >500 msec.
Uncontrolled ischemic heart disease or uncontrolled symptomatic congestive heart failure (Class III or IV as defined by the New York Heart Association functional classification system).
History of stroke or cerebrovascular accident within 6 months prior to first dose of study treatment.
Known serious active infection such as, but not limited to, human immunodeficiency virus (HIV) (e.g., viral load indicative of HIV, HIV 1/2 antibodies), Hepatitis B (e.g., Hepatitis B surface antigen reactive or Hepatitis B DNA detected), Hepatitis C (e.g., Hepatitis C ribonucleic acid [quantitative] is detected) or tuberculosis.
Severe infection within 4 weeks prior to enrollment, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia.
Other uncontrolled serious chronic disease or psychiatric condition that in the Investigator's opinion could affect participant safety, compliance, or follow-up in the protocol.
Known hypersensitivity or allergy to irinotecan, SN-38, trilaciclib, or sacituzumab govitecan-hziy or any excipients of the aforementioned medications
Prior hematopoietic stem cell or bone marrow transplantation.
Pregnant or lactating women
Major surgical procedure, open biopsy, or significant traumatic injury within 4 weeks prior to study treatment start, or anticipation of the need for major surgical procedure during the course of the study.
Received a live, attenuated vaccine within 4 weeks prior to the first dose of study treatment or anticipation that such a vaccine will be required during the study treatment period:
a. Influenza vaccination should be given during influenza season only (approximately October through May in the Northern Hemisphere).
Legal incapacity or limited legal capacity.
Participants who are investigational site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the Investigator, or participants who are employees of G1 Therapeutics, Inc. directly involved in the conduct of the study.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Clinical Conduct | G1 Therapeutics, Inc. | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Ironwood Physicians | Chandler | Arizona | 85224 | United States | ||
| Comprehensive Blood & Cancer Center |
The study included 3 study phases: Screening Phase, Treatment Phase, and Survival Follow-up Phase. The Treatment Phase began on the day of the first study treatment dose and was completed at the Safety Follow-up Visit. The first Survival Follow-up assessment occurred approximately 3 months after the Safety Follow-Up Visit.
Recruitment took place from Q4 2021 until Q2 2024 in 20 different centers.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Trilaciclib + Sacituzumab Govitecan-hziy | Participants received trilaciclib + sacituzumab govitecan-hziy on Days 1 and 8 of a 21-day cycle. Trilaciclib was administered first, followed by sacituzumab govitecan-hziy. Administer diluted trilaciclib solution as a 30-minute IV infusion completed within 4 hours prior to the start of sacituzumab govitecan-hziy. Trilaciclib: Single-use, sterile powder reconstituted and further diluted with 250 mL of normal saline (sodium chloride solution 0.9%) or D5W Sacituzumab Govitecan-hziy: 10 mg/kg reconstituted to a concentration of 1.1 mg/mL to 3.4 mg/mL in normal saline |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | Nov 15, 2021 | Nov 4, 2024 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Sacituzumab Govitecan-hziy | Drug | 10 milligram per kilogram (mg/kg) reconstituted to a concentration of 1.1 mg/mL to 3.4 mg/mL in normal saline |
|
|
| Clinical Benefit Rate (CBR) | CBR was defined as the percentage of participants with the best overall response of confirmed complete response, confirmed partial response, or stable disease lasting 24 weeks or longer since the first date of study drug administration per RECIST v1.1 | Up to approximately 24 months |
| Duration of Objective Response (DOR) | DOR was the time between the first objective response of CR or PR (confirmed) and the first date that progressive disease was documented or death, whichever comes first. DOR was only analyzed for the patients who had achieved objective responses. | Up to approximately 24 months |
| Overall Survival (OS) | OS was defined as the time (months) from the date of the first dose of the study drug to the date of death for participants who died in the study due to any cause or the time to the last contact date known to be alive for those participants who survived as of the data cutoff date for the planned OS analysis (censored cases). | Up to approximately 24 months |
| Number of Participants With Occurrence of Severe Neutropenia (SN) | Occurrences of SN in Cycles 1 and 2 and the overall study are reported. | Up to approximately 24 months |
| Participants With At Least One Occurrence of Febrile Neutropenia (FN) | FN was defined as a complication of cancer treatment. It is the development of a fever, alongside other signs of infection such as feeling unwell, shivers, and shakes in a participant with neutropenia. | Up to approximately 24 months |
| Occurrence of Granulocyte Colony-stimulating Factor (G-CSF) Administration | The number of cycles with G-CSF administrations for a participant was the total number of cycles where the participant received at least one dose of G-CSF, for participants who did not have any G-CSF use and those who were enrolled but did not receive any study treatment, a value of 0 was assigned. | Up to approximately 24 months |
| Occurrence of Grade 3 or 4 Decreased Hemoglobin (Hgb) | The occurrence of Grade 3 or 4 decreased hemoglobin (Hgb) for a participant was defined as having at least one Hgb value that was < 8.0 gram per deciliter (g/dL) among all scheduled or unscheduled assessments. It was a binary random variable (Yes or No). | Up to approximately 24 months |
| Number of RBC Transfusions | Based on the NCCN Clinical Practice Guidelines in Oncology for Hematopoietic Growth Factors Version 2.2020 and the AABB Clinical Practice Guidelines, the following RBC transfusion thresholds were recommended; however, the participant's clinical situation should always be the primary guiding factor when deciding to transfuse.
| From Week 5 up to approximately 24 months |
| Number of Participants With Occurrence of Erythropoiesis-Stimulating Agent (ESA) Administration | If participants experienced chemotherapy-induced anemia (hemoglobin level <10 g/dL) after receiving the first dose of study treatment, ESAs may be used per ASCO guidelines to improve hematopoietic response and reduce the likelihood of RBC transfusion. | Up to approximately 24 months |
| Number of Participants With Occurrence of Grade 3 and 4 Decrease of Platelets | Grade 3 shows signs of mucosal bleeding, such as blood crusting in nostrils or nosebleeds, petechiae or purpura in the mouth, blood in the urine or stool, and heavy periods. Grade 4 shows signs of more severe mucosal bleeding or suspected internal bleeding, such as in the brain or lungs that requires immediate medical attention. | Up to approximately 24 months |
| Number of Platelet Transfusions | Platelet transfusion is recommended at a threshold of ≤10 x 10^9/L. Platelets should also be transfused in any participant who was bleeding with a platelet count <50 x 10^9/L (100 x 10^9/L for central nervous system or ocular bleeding). | Up to approximately 24 months |
| Number of Participants With Occurrence of Serious Infections | Participants experienced chemotherapy-induced myelosuppression faced severe clinical consequences such as serious infections are reported. | Up to approximately 24 months |
| Number of Participants Administered IV Antibiotics | Up to approximately 24 months |
| Number of Participants With Treatment-emergent Serious Adverse Events (SAEs) and Non-serious Adverse Events (NSAEs) | AEs are defined as those events occurring or worsening after treatment has begun in the study. An AE is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. | From first administration of study treatment (Day 1) up to approximately 24 months |
| Bakersfield |
| California |
| 93309 |
| United States |
| Los Angeles Hematology Oncology Medical Group | Los Angeles | California | 90017 | United States |
| Valkyrie Clinical Trials | Los Angeles | California | 90067 | United States |
| UCLA Hematology/Oncology Parkside | Santa Monica | California | 90404 | United States |
| PIH Health | Whittier | California | 90602 | United States |
| Rocky Mountain Cancer Centers | Denver | Colorado | 80220 | United States |
| Memorial Healthcare System | Hollywood | Florida | 33021 | United States |
| Orlando Health Cancer Institute | Orlando | Florida | 32806 | United States |
| Duly Health and Care | Joliet | Illinois | 60435 | United States |
| New England Cancer Specialists | Scarborough | Maine | 04704 | United States |
| Minnesota Oncology Hematology, P.A. | Woodbury | Minnesota | 55125 | United States |
| Comprehensive Cancer Centers of Nevada | Las Vegas | Nevada | 89128 | United States |
| Northwest Cancer Specialists, PC | Tigard | Oregon | 97223 | United States |
| Texas Oncology - Austin Central | Austin | Texas | 78731 | United States |
| Texas Oncology - Baylor Charles A. Sammons Cancer Center | Dallas | Texas | 75246 | United States |
| Texas Oncology - Longview Cancer Center | Longview | Texas | 75601 | United States |
| Inova Schar Cancer Institute | Fairfax | Virginia | 22031 | United States |
| Virginia Oncology Associates | Norfolk | Virginia | 23502 | United States |
| Oncology and Hematology Associates of Southwest Virginia, Inc | Roanoke | Virginia | 24014 | United States |
| Multicare Health System | Auburn | Washington | 98001 | United States |
| Northwest Medical Specialties, PLLC | Tacoma | Washington | 98405 | United States |
| COMPLETED |
|
| NOT COMPLETED |
|
|
Full Analysis Set (FAS): included all enrolled participantswho were administered at least 1 dose of study drug.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Trilaciclib + Sacituzumab Govitecan-hziy | Participants received trilaciclib + sacituzumab govitecan-hziy on Days 1 and 8 of a 21-day cycle. Trilaciclib was administered first, followed by sacituzumab govitecan-hziy. Administer diluted trilaciclib solution as a 30-minute IV infusion completed within 4 hours prior to the start of sacituzumab govitecan-hziy. Trilaciclib: Single-use, sterile powder reconstituted and further diluted with 250 mL of normal saline (sodium chloride solution 0.9%) or D5W Sacituzumab Govitecan-hziy: 10 mg/kg reconstituted to a concentration of 1.1 mg/mL to 3.4 mg/mL in normal saline |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Standard Deviation | years |
| |||||||||||||||||
| Sex/Gender, Customized | Count of Participants | Participants |
| ||||||||||||||||||
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
| ||||||||||||||||||
| Race (NIH/OMB) | Count of Participants | Participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Progression Free Survival (PFS) | Progression free survival was defined as the time (months) from the date of the first dose of the study drug to the date of documented radiographic disease progression per RECIST v1.1 or death due to any cause, whichever comes first. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions | FAS: included all enrolled participants who were administered at least 1 dose of study drug. | Posted | Median | 95% Confidence Interval | months | Up to approximately 23 months |
|
|
| |||||||||||||||||||||||||
| Secondary | Objective Response Rate (ORR) | ORR was defined as the percentage of participants with the best overall response of confirmed complete response or confirmed partial response per RECIST v1.1 Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. | The Response Evaluable (RE) population included all participants who were in the FAS and who had measurable (target) tumor lesion(s) at the baseline tumor assessment and either (i) had at least 1 post-baseline tumor assessment, or (ii) do not have post-dose tumor assessment but had clinical progression as noted by the Investigator, or (iii) died due to disease progression prior to their first post-baseline tumor scan. | Posted | Number | 95% Confidence Interval | percentage of participants | Up to approximately 24 months |
| |||||||||||||||||||||||||||
| Secondary | Clinical Benefit Rate (CBR) | CBR was defined as the percentage of participants with the best overall response of confirmed complete response, confirmed partial response, or stable disease lasting 24 weeks or longer since the first date of study drug administration per RECIST v1.1 | RE: population included all participants who were in the FAS and who had measurable (target) tumor lesion(s) at the baseline tumor assessment and either (i) had at least 1 post-baseline tumor assessment, or (ii) did not have post-dose tumor assessment but had clinical progression as noted by the Investigator, or (iii) died due to disease progression prior to their first post-baseline tumor scan. | Posted | Number | 95% Confidence Interval | percentage of participants | Up to approximately 24 months |
|
| ||||||||||||||||||||||||||
| Secondary | Duration of Objective Response (DOR) | DOR was the time between the first objective response of CR or PR (confirmed) and the first date that progressive disease was documented or death, whichever comes first. DOR was only analyzed for the patients who had achieved objective responses. | The Response Evaluable (RE) population included all participants who were in the FAS and who had measurable (target) tumor lesion(s) at the baseline tumor assessment and either (i) had at least 1 post-baseline tumor assessment, or (ii) did not have post-dose tumor assessment but had clinical progression as noted by the Investigator, or (iii) died due to disease progression prior to their first post-baseline tumor scan. DOR was only analyzed for the participants who had achieved OR. | Posted | Median | 95% Confidence Interval | months | Up to approximately 24 months |
| |||||||||||||||||||||||||||
| Secondary | Overall Survival (OS) | OS was defined as the time (months) from the date of the first dose of the study drug to the date of death for participants who died in the study due to any cause or the time to the last contact date known to be alive for those participants who survived as of the data cutoff date for the planned OS analysis (censored cases). | FAS: included all enrolled participants who were administered at least 1 dose of study drug. | Posted | Median | 95% Confidence Interval | months | Up to approximately 24 months |
|
| ||||||||||||||||||||||||||
| Secondary | Number of Participants With Occurrence of Severe Neutropenia (SN) | Occurrences of SN in Cycles 1 and 2 and the overall study are reported. | FAS: included all enrolled participants who were administered at least 1 dose of study drug. | Posted | Count of Participants | Participants | Up to approximately 24 months |
|
| |||||||||||||||||||||||||||
| Secondary | Participants With At Least One Occurrence of Febrile Neutropenia (FN) | FN was defined as a complication of cancer treatment. It is the development of a fever, alongside other signs of infection such as feeling unwell, shivers, and shakes in a participant with neutropenia. | FAS: included all enrolled participants who were administered at least 1 dose of study drug. | Posted | Count of Participants | Participants | Up to approximately 24 months |
|
| |||||||||||||||||||||||||||
| Secondary | Occurrence of Granulocyte Colony-stimulating Factor (G-CSF) Administration | The number of cycles with G-CSF administrations for a participant was the total number of cycles where the participant received at least one dose of G-CSF, for participants who did not have any G-CSF use and those who were enrolled but did not receive any study treatment, a value of 0 was assigned. | FAS: included all enrolled participants who were administered at least 1 dose of study drug. | Posted | Count of Participants | Participants | Up to approximately 24 months |
|
| |||||||||||||||||||||||||||
| Secondary | Occurrence of Grade 3 or 4 Decreased Hemoglobin (Hgb) | The occurrence of Grade 3 or 4 decreased hemoglobin (Hgb) for a participant was defined as having at least one Hgb value that was < 8.0 gram per deciliter (g/dL) among all scheduled or unscheduled assessments. It was a binary random variable (Yes or No). | FAS: included all enrolled participants who were administered at least 1 dose of study drug. | Posted | Count of Participants | Participants | Up to approximately 24 months |
|
| |||||||||||||||||||||||||||
| Secondary | Number of RBC Transfusions | Based on the NCCN Clinical Practice Guidelines in Oncology for Hematopoietic Growth Factors Version 2.2020 and the AABB Clinical Practice Guidelines, the following RBC transfusion thresholds were recommended; however, the participant's clinical situation should always be the primary guiding factor when deciding to transfuse.
| Data were not collected for this outcome measure nor conducted as part of the final analysis as they were not deemed critical for the aCSR. | Posted | From Week 5 up to approximately 24 months |
| ||||||||||||||||||||||||||||||
| Secondary | Number of Participants With Occurrence of Erythropoiesis-Stimulating Agent (ESA) Administration | If participants experienced chemotherapy-induced anemia (hemoglobin level <10 g/dL) after receiving the first dose of study treatment, ESAs may be used per ASCO guidelines to improve hematopoietic response and reduce the likelihood of RBC transfusion. | Data were not collected for this outcome measure nor conducted as part of the final analysis as they were not deemed critical for the aCSR. | Posted | Up to approximately 24 months |
|
| |||||||||||||||||||||||||||||
| Secondary | Number of Participants With Occurrence of Grade 3 and 4 Decrease of Platelets | Grade 3 shows signs of mucosal bleeding, such as blood crusting in nostrils or nosebleeds, petechiae or purpura in the mouth, blood in the urine or stool, and heavy periods. Grade 4 shows signs of more severe mucosal bleeding or suspected internal bleeding, such as in the brain or lungs that requires immediate medical attention. | Data were not collected for this outcome measure nor conducted as part of the final analysis as they were not deemed critical for the aCSR. | Posted | Up to approximately 24 months |
|
| |||||||||||||||||||||||||||||
| Secondary | Number of Platelet Transfusions | Platelet transfusion is recommended at a threshold of ≤10 x 10^9/L. Platelets should also be transfused in any participant who was bleeding with a platelet count <50 x 10^9/L (100 x 10^9/L for central nervous system or ocular bleeding). | Data were not collected for this outcome measure nor conducted as part of the final analysis as they were not deemed critical for the aCSR. | Posted | Up to approximately 24 months |
|
| |||||||||||||||||||||||||||||
| Secondary | Number of Participants With Occurrence of Serious Infections | Participants experienced chemotherapy-induced myelosuppression faced severe clinical consequences such as serious infections are reported. | Data were not collected for this outcome measure nor conducted as part of the final analysis as they were not deemed critical for the aCSR. | Posted | Up to approximately 24 months |
|
| |||||||||||||||||||||||||||||
| Secondary | Number of Participants Administered IV Antibiotics | Data were not collected for this outcome measure nor conducted as part of the final analysis as they were not deemed critical for the aCSR. | Posted | Up to approximately 24 months |
|
| ||||||||||||||||||||||||||||||
| Secondary | Number of Participants With Treatment-emergent Serious Adverse Events (SAEs) and Non-serious Adverse Events (NSAEs) | AEs are defined as those events occurring or worsening after treatment has begun in the study. An AE is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. | Safety Population; included all enrolled participants who received at least 1 dose of study drug. | Posted | Number | Count of participants | From first administration of study treatment (Day 1) up to approximately 24 months |
|
|
From the first administration of study treatment (Day 1) up to the end of the study visit, approximately 132 weeks.
The safety population included all enrolled participants who received at least 1 dose of study drug.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Trilaciclib + Sacituzumab Govitecan-hziy | Participants received trilaciclib + sacituzumab govitecan-hziy on Days 1 and 8 of a 21-day cycle. Trilaciclib was administered first, followed by sacituzumab govitecan-hziy. Administer diluted trilaciclib solution as a 30-minute IV infusion completed within 4 hours prior to the start of sacituzumab govitecan-hziy. Trilaciclib: Single-use, sterile powder reconstituted and further diluted with 250 mL of normal saline (sodium chloride solution 0.9%) or D5W Sacituzumab Govitecan-hziy: 10 mg/kg reconstituted to a concentration of 1.1 mg/mL to 3.4 mg/mL in normal saline | 21 | 30 | 6 | 30 | 29 | 30 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Breast cellulitis | Infections and infestations | MedDRA 26.1 | Systematic Assessment |
| |
| Sepsis | Infections and infestations | MedDRA 26.1 | Systematic Assessment |
| |
| Dizziness | Nervous system disorders | MedDRA 26.1 | Systematic Assessment |
| |
| Hypoaesthesia | Nervous system disorders | MedDRA 26.1 | Systematic Assessment |
| |
| Febrile neutropenia | Blood and lymphatic system disorders | MedDRA 26.1 | Systematic Assessment |
| |
| Atrial fibrillation | Cardiac disorders | MedDRA 26.1 | Systematic Assessment |
| |
| Diarrhoea | Gastrointestinal disorders | MedDRA 26.1 | Systematic Assessment |
| |
| Nausea | Gastrointestinal disorders | MedDRA 26.1 | Systematic Assessment |
| |
| Vomiting | Gastrointestinal disorders | MedDRA 26.1 | Systematic Assessment |
| |
| Acute respiratory failure | Respiratory, thoracic and mediastinal disorders | MedDRA 26.1 | Systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Nausea | Gastrointestinal disorders | MedDRA 26.1 | Systematic Assessment |
| |
| Diarrhoea | Gastrointestinal disorders | MedDRA 26.1 | Systematic Assessment |
| |
| Constipation | Gastrointestinal disorders | MedDRA 26.1 | Systematic Assessment |
| |
| Vomiting | Gastrointestinal disorders | MedDRA 26.1 | Systematic Assessment |
| |
| Abdominal pain | Gastrointestinal disorders | MedDRA 26.1 | Systematic Assessment |
| |
| Abdominal pain upper | Gastrointestinal disorders | MedDRA 26.1 | Systematic Assessment |
| |
| Dyspepsia | Gastrointestinal disorders | MedDRA 26.1 | Systematic Assessment |
| |
| Abdominal distension | Gastrointestinal disorders | MedDRA 26.1 | Systematic Assessment |
| |
| Dry mouth | Gastrointestinal disorders | MedDRA 26.1 | Systematic Assessment |
| |
| Gastrooesophageal reflux disease | Gastrointestinal disorders | MedDRA 26.1 | Systematic Assessment |
| |
| Stomatitis | Gastrointestinal disorders | MedDRA 26.1 | Systematic Assessment |
| |
| Fatigue | General disorders | MedDRA 26.1 | Systematic Assessment |
| |
| Pyrexia | General disorders | MedDRA 26.1 | Systematic Assessment |
| |
| Asthenia | General disorders | MedDRA 26.1 | Systematic Assessment |
| |
| Chills | General disorders | MedDRA 26.1 | Systematic Assessment |
| |
| Localised oedema | General disorders | MedDRA 26.1 | Systematic Assessment |
| |
| Oedema peripheral | General disorders | MedDRA 26.1 | Systematic Assessment |
| |
| Headache | Nervous system disorders | MedDRA 26.1 | Systematic Assessment |
| |
| Dizziness | Nervous system disorders | MedDRA 26.1 | Systematic Assessment |
| |
| Dysgeusia | Nervous system disorders | MedDRA 26.1 | Systematic Assessment |
| |
| Hypoaesthesia | Nervous system disorders | MedDRA 26.1 | Systematic Assessment |
| |
| Neuropathy peripheral | Nervous system disorders | MedDRA 26.1 | Systematic Assessment |
| |
| Restless legs syndrome | Nervous system disorders | MedDRA 26.1 | Systematic Assessment |
| |
| Back pain | Musculoskeletal and connective tissue disorders | MedDRA 26.1 | Systematic Assessment |
| |
| Arthralgia | Musculoskeletal and connective tissue disorders | MedDRA 26.1 | Systematic Assessment |
| |
| Myalgia | Musculoskeletal and connective tissue disorders | MedDRA 26.1 | Systematic Assessment |
| |
| Chest wall necrosis | Musculoskeletal and connective tissue disorders | MedDRA 26.1 | Systematic Assessment |
| |
| Muscular weakness | Musculoskeletal and connective tissue disorders | MedDRA 26.1 | Systematic Assessment |
| |
| Neck pain | Musculoskeletal and connective tissue disorders | MedDRA 26.1 | Systematic Assessment |
| |
| Pain in extremity | Musculoskeletal and connective tissue disorders | MedDRA 26.1 | Systematic Assessment |
| |
| Cough | Respiratory, thoracic and mediastinal disorders | MedDRA 26.1 | Systematic Assessment |
| |
| Oropharyngeal pain | Respiratory, thoracic and mediastinal disorders | MedDRA 26.1 | Systematic Assessment |
| |
| Dyspnoea | Respiratory, thoracic and mediastinal disorders | MedDRA 26.1 | Systematic Assessment |
| |
| Rhinorrhoea | Respiratory, thoracic and mediastinal disorders | MedDRA 26.1 | Systematic Assessment |
| |
| Alopecia | Skin and subcutaneous tissue disorders | MedDRA 26.1 | Systematic Assessment |
| |
| Dry skin | Skin and subcutaneous tissue disorders | MedDRA 26.1 | Systematic Assessment |
| |
| Rash | Skin and subcutaneous tissue disorders | MedDRA 26.1 | Systematic Assessment |
| |
| Erythema | Skin and subcutaneous tissue disorders | MedDRA 26.1 | Systematic Assessment |
| |
| Rash maculo-papular | Skin and subcutaneous tissue disorders | MedDRA 26.1 | Systematic Assessment |
| |
| COVID-19 | Infections and infestations | MedDRA 26.1 | Systematic Assessment |
| |
| Urinary tract infection | Infections and infestations | MedDRA 26.1 | Systematic Assessment |
| |
| Upper respiratory tract infection | Infections and infestations | MedDRA 26.1 | Systematic Assessment |
| |
| Decreased appetite | Metabolism and nutrition disorders | MedDRA 26.1 | Systematic Assessment |
| |
| Dehydration | Metabolism and nutrition disorders | MedDRA 26.1 | Systematic Assessment |
| |
| Hypokalaemia | Metabolism and nutrition disorders | MedDRA 26.1 | Systematic Assessment |
| |
| Hyperglycaemia | Metabolism and nutrition disorders | MedDRA 26.1 | Systematic Assessment |
| |
| Neutrophil count decreased | Investigations | MedDRA 26.1 | Systematic Assessment |
| |
| White blood cell count decreased | Investigations | MedDRA 26.1 | Systematic Assessment |
| |
| Alanine aminotransferase increased | Investigations | MedDRA 26.1 | Systematic Assessment |
| |
| Aspartate aminotransferase increased | Investigations | MedDRA 26.1 | Systematic Assessment |
| |
| Insomnia | Psychiatric disorders | MedDRA 26.1 | Systematic Assessment |
| |
| Palpitations | Cardiac disorders | MedDRA 26.1 | Systematic Assessment |
| |
| Atrial fibrillation | Cardiac disorders | MedDRA 26.1 | Systematic Assessment |
| |
| Sinus bradycardia | Cardiac disorders | MedDRA 26.1 | Systematic Assessment |
| |
| Neutropenia | Blood and lymphatic system disorders | MedDRA 26.1 | Systematic Assessment |
| |
| Anaemia | Blood and lymphatic system disorders | MedDRA 26.1 | Systematic Assessment |
| |
| Leukopenia | Blood and lymphatic system disorders | MedDRA 26.1 | Systematic Assessment |
| |
| Flushing | Vascular disorders | MedDRA 26.1 | Systematic Assessment |
| |
| Hot flush | Vascular disorders | MedDRA 26.1 | Systematic Assessment |
| |
| Hypotension | Vascular disorders | MedDRA 26.1 | Systematic Assessment |
| |
| Breast pain | Reproductive system and breast disorders | MedDRA 26.1 | Systematic Assessment |
| |
| Fall | Injury, poisoning and procedural complications | MedDRA 26.1 | Systematic Assessment |
|
Investigator agrees to submit any disclosure to Sponsor for review at least thirty (30) days prior to submission. Within sixty (60) days of its receipt, Sponsor can provide feedback on any disclosure Sponsor may require Investigator to remove, Confidential Information (other than study data), and/or to delay the proposed publication or presentation for an additional sixty (60) days to enable Sponsor to seek patent protection for inventions.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Clinical Trial Info. | G1 Therapeutics, Inc. | 919-213-9835 | clinicalinfo@g1therapeutics.com |
| Prot_000.pdf |
| SAP | No | Yes | No | Statistical Analysis Plan | Jun 4, 2024 | Nov 4, 2024 | SAP_001.pdf |
Not provided
| ID | Term |
|---|---|
| D064726 | Triple Negative Breast Neoplasms |
| ID | Term |
|---|---|
| D001943 | Breast Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D001941 | Breast Diseases |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C000708352 | trilaciclib |
| C000608132 | sacituzumab govitecan |
Not provided
Not provided
Not provided
| Unknown or Not Reported |
|
| Native Hawaiian or Other Pacific Islander |
|
| Black or African American |
|
| White |
|
| More than one race |
|
| Unknown or Not Reported |
|
| Units | Counts |
|---|
| Participants |
|
|
| Participants |
|
|
| Units |
|---|
| Counts |
|---|
| Participants |
|
|
|
|
|
|
|
| Units |
|---|
| Counts |
|---|
| Participants |
|
|